779 patents
Page 13 of 39
Utility
Compounds for the Treatment of Braf-associated Diseases and Disorders
15 Sep 22
Patrick Michael BARBOUR, Katie Keaton BROWN, Adam Wade COOK, Erik James HICKEN, Dean Russell KAHN, Ellen Ruth LAIRD, Andrew Terrance METCALF, David Austin MORENO, Bradley Jon NEWHOUSE, Spencer Phillip PAJK, Brett Joseph PRIGARO, Li REN, Eugene TARLTON
Filed: 16 May 22
Utility
ANTI-AVBETA8 Antibodies and Compositions and Uses Thereof
15 Sep 22
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to αvβ8 integrin.
Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
Filed: 13 May 22
Utility
Anti-proliferative agents for treating PAH
13 Sep 22
Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
Steven Martin Evans
Filed: 4 Nov 20
Utility
Antibodies specific for CD3 and uses thereof
6 Sep 22
The present invention provides novel antibodies that specifically bind to CD3 and uses thereof.
James Reasoner Apgar, Fang Jin, Madan Katragadda, Divya Mathur, Lioudmila Gennadievna Tchistiakova
Filed: 21 May 19
Utility
Toll-like Receptor Agonists
1 Sep 22
The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
Omar Ahmad, Andrew Fensome, Erik Alphie LaChapelle, Ethan Lawrence Fisher, Rayomand J. Unwalla, Jun Xiao, Lei Zhang
Filed: 6 May 22
Utility
Unknown
30 Aug 22
The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation.
Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
Filed: 1 Oct 20
Utility
Antibodies specific for FLT3 and their uses
23 Aug 22
The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3).
Danielle Elizabeth Dettling, Yik Andy Yeung, Kristian Todd Poulsen, Veena Krishnamoorthy, Cesar Adolfo Sommer
Filed: 31 May 18
Utility
Nitrile-Containing Antiviral Compounds
18 Aug 22
Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
Filed: 22 Apr 22
Utility
Methods of Treating Neurofibromatosis with N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE
18 Aug 22
The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.
Erwin IRDAM
Filed: 24 Jun 21
Utility
Immunogenic compositions for use in pneumococcal vaccines
16 Aug 22
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates.
David Cooper, Kathrin Ute Jansen, Michael William Pride
Filed: 5 Jan 18
Utility
Compounds for the treatment of BRAF-associated diseases and disorders
16 Aug 22
Patrick Michael Barbour, Katie Keaton Brown, Adam Wade Cook, Erik James Hicken, Dean Russell Kahn, Ellen Ruth Laird, Andrew Terrance Metcalf, David Austin Moreno, Bradley Jon Newhouse, Spencer Phillip Pajk, Brett Joseph Prigaro, Li Ren, Eugene Tarlton
Filed: 24 Jun 20
Utility
Sulfonyl Amide Derivatives for the Treatment of Abnormal Cell Growth
11 Aug 22
Michael Joseph Luzzio, Kevin Daniel Freeman-Cook, Samit Kumar Bhattacharya, Matthew Merrill Hayward, Catherine Angela Hulford, Christopher Lowell Autry, Xumiao Zhao, Jun Xiao, Kendra Louise Nelson
Filed: 27 Aug 21
Utility
Protein Tyrosine Phosphatase Inhibitors
11 Aug 22
James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
Filed: 13 Apr 22
Utility
Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives
11 Aug 22
Oleg Brodsky, Samantha Elizabeth Greasley, Robert Louis Hoffman, Pei-Pei Kung, Paul Francis Richardson, Paul Anthony Stupple
Filed: 17 Jun 20
Utility
PD-1 Axis Binding Antagonist to Treat Cancer with Genetic Mutations In Specific Genes
4 Aug 22
The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers.
Marat Alimzhanov, Keith Anthony Ching, Alessandra Di Pietro, Xinmeng Mu, Paul Brian Robbins
Filed: 29 May 20
Utility
Combination Therapies Using CDK Inhibitors
4 Aug 22
This invention relates to a method for treating cancer by administering a CDK4/6 or a CDK2/4/6 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an OX40 agonist and/or a 4-1BB agonist to a subject in need thereof.
Stephen George Dann, Cecilia Marianne Oderup, Shahram Salek-Ardakani
Filed: 20 May 20
Utility
Combination Therapies Using CDK Inhibitors
28 Jul 22
This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.
Stephen George Dann, Cecilia Marianne Oderup, Shahram Salek-Ardakani
Filed: 21 May 20
Utility
CDK2/4/6 inhibitors
26 Jul 22
Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
Filed: 27 Aug 20
Utility
Chimeric antigen receptors targeting CD70
26 Jul 22
The disclosure provides CARs (CARs) that specifically bind to CD70.
Surabhi Srivatsa Srinivasan, Niranjana Aditi Nagarajan, Siler Panowski, Yoon Park, Tao Sai, Barbra Johnson Sasu, Thomas John Van Blarcom, Mathilde Brunnhilde Dusseaux, Roman Ariel Galetto
Filed: 31 Jan 19
Utility
Hydroxylated and Methoxylated Pyrimidyl Cyclopentanes As Akt Protein Kinase Inhibitors
21 Jul 22
Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
Filed: 23 Aug 21